Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Protriptyline
Drug ID BADD_D01872
Description Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, alpha1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.
Indications and Usage For the treatment of depression.
Marketing Status Prescription; Discontinued
ATC Code N06AA11
DrugBank ID DB00344
KEGG ID D08447
MeSH ID D011530
PubChem ID 4976
TTD Drug ID D00MYQ
NDC Product Code Not Available
Synonyms Protriptyline | Vivactil | Protriptyline Hydrochloride | Hydrochloride, Protriptyline
Chemical Information
Molecular Formula C19H21N
CAS Registry Number 438-60-8
SMILES CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Accommodation disorder06.02.04.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrioventricular block02.03.01.002--Not Available
Body temperature increased13.15.01.001--Not Available
Breast enlargement21.05.04.001--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Delusion19.10.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug withdrawal syndrome19.07.02.011; 08.06.02.004--Not Available
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Eosinophilia01.02.04.001--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages